ViroCell and GOSH gain MHRA manufacturing approval

November 1, 2023
Manufacturing and Production Great Ormand Street Hospital, MHRA, Pharmacy, ViroCell, manufacturing, viral vectors

ViroCell Biologics has announced that it can now manufacture and export viral vectors from Great Ormand Street Hospital’s (GOSH) state-of-the-art …

AstraZeneca and Cellectis to collaborate for cell therapy and genomic medicine development

November 1, 2023
Research and Development AstraZeneca, CGT, Pharmacy, cell therapy, cellectis, genomic medicine

AstraZeneca has announced a collaboration and investment agreement with Cellectis for the development of next generation cell and gene therapeutics …

Allyx Therapeutics shares phase 1a trial data for Alzheimer’s treatment

October 31, 2023
Medical Communications Allyx Therpeutics, Alzheimer's disease, Neurology, clinical trial

Allyx Therapeutics has announced phase 1a single ascending dose study results at the 16th Clinical Trials on Alzheimer’s Disease (CTAD) …

NMPA approves CStone’s Cejemly for lymphoma treatment

October 31, 2023
Medical Communications CStone, Cejemly, NMPA, Oncology, lymphoma

CStone Pharmaceuticals has announced that the National Medical Products Administration (NMPA) of China has approved its anti-PD-L1 antibody Cejemly (sugemalimab) …

First patient enrolled in Boan Biotech’s phase 3 trial for Nivolumab in China

October 30, 2023
Research and Development Boan Biotech, China, Oncology, clinical trial, nivolumab

Boan Biotech has announced that the first patient has been enrolled in its phase 3 trial of its Nivolumab injection …

GSK shares results from phase 3 RUBY trial of Jemperli for endometrial cancer treatment

October 30, 2023
Medical Communications Cancer, GSK, Jemperli, Oncology, endometrial cancer

GSK has announced positive headline results from an analysis of part 1 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial which assessed …

Roche’s Vabysmo approved by FDA for retinal vein occlusion treatment

October 27, 2023
Medical Communications FDA, Opthalmology, Roche, Vabysmo, retinal vein occlusion

Roche has announced that the US Food and Drug Administration (FDA) has approved Vabysmo (farcimab) for the treatment of macular …

Eli Lilly’s Omvoh receives FDA approval for ulcerative colitis treatment

October 27, 2023
Medical Communications Eli Lilly, FDA, Gastrointestinal tract, Omvoh, ulcerative colitis

Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved Omvoh (mirikizumab-mrkz) infusion (300mg/15mL)/injection (100mg/mL) for …

China’s NMPA approves ViiV Healthcare’s Vocabria in combination with Rekambys for HIV treatment

October 26, 2023
Research and Development HIV, HIV/AIDS, NMPA, ViiV Healthcare, Vocabria

ViiV Healthcare has announced that the National Medical Products Administration (NMPA) of China has approved Vocabria (cabotegravir injection) used in …

robina-weermeijer-so1l3jsdd3y-unsplash_2

Eisai shares new data for Leqembi for Alzheimer’s treatment

October 26, 2023
Research and Development Alzheimer's, Biogen, Eisai, Neurology, lecanemab

Eisai and Biogen have announced that Eisai has shared new data for Leqembi (lecanemab-irmb) 100mg/mL injection for intravenous (IV) use …

FDA approves Servier Pharmaceuticals’ new MDS therapy

October 25, 2023
Medical Communications FDA, Oncology, Servier Pharmaceuticals, myelodysplastic syndromes

The US Food and Drug Administration (FDA) has announced that it has approved Servier Pharmaceuticals’ Tibsovo (ivosidenib) for the treatment …

GSK shares new data for RSV vaccine Arexvy

October 25, 2023
Research and Development Arexvy, GSK, Immunology, RSV, Vaccine

GSK announced positive results from its phase 3 trial which assessed the immune response and safety of Arexvy, its respiratory …

AstraZeneca’s sBLA for FluMist Quadrivalent accepted by FDA

October 24, 2023
Medical Communications AstraZeneca, FDA, FluMist, Immunology, flu vaccine, sBLA

AstraZeneca has announced that the US Food and Drug Administration (FDA) has accepted for review its Supplemental Biologics License Agreement …

glsun-mall-9xmv81sz5fw-unsplash

Samsung Biologics and Kurma Partners announce collaboration for development and manufacturing of biologics

October 24, 2023
Business Services Kurma Partners, Pharmacy, Samsung BioLogics

Samsung Biologics and Kurma Partners have announced a strategic partnership for the development and manufacturing of biologics for Kurma Partners’ …

Roche announces acquisition of Telavant

October 23, 2023
Business Services Gastrointestinal tract, Roche, Telavant

Roche has announced that it has entered into a definitive agreement to acquire Telavant Holdings, a Roivant company, owned by …

AstraZeneca and Daiichi Sankyo’s Enhertu approved in EU for treatment of HER2-mutant NSCLC

October 23, 2023
Research and Development AstraZeneca, Daiichi Sankyo, Enhertu, NSCLC, Oncology

AstraZeneca and Daiichi Sankyo have announced that Enhertu (trastuzumab deruxtecan) has been approved in the EU as a monotherapy for …

Genentech shares data from phase 3 trials of Vabysmo for retinal vein occlusion treatment

October 10, 2023
Research and Development Genentech, Opthalmology, Vabysmo, phase 3 trial, retinal vein occlusion

Genentech has announced positive topline long-term results from its global phase 3 BALATON and COMINO trials which assessed extended treatment …

First patient dosed in Transgene and BioInvent’s phase 1 trial

October 10, 2023
Research and Development BioInvent, Oncology, Transgene, oncology, phase 1 trial

Transgene and BioInvent have announced that the first patient has been treated in the phase 1 part B clinical trial …

BMS acquires Mirati Therapeutics for $4.8bn

October 9, 2023
Business Services BMS, Mirati Therapeutics, Oncology, acquisition, bristol myers squibb, oncology

Bristol Myers Squibb (BMS) and Mirati Therapeutics have announced that they have entered into a definitive agreement under which BMS …

GSK and Zhifei partner for shingles vaccine promotion in China

October 9, 2023
Medical Communications GSK, Immunology, Shingrix, Vaccine, Zhifei, shingles

GSK has announced that it has come to an exclusive agreement with Chingqing Zhifei Biological Products to co-promote GSK’s shingles …

The Gateway to Local Adoption Series

Latest content